CatalystFDA/Bio

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Ziihera’s overall survival beat over trastuzumab, raising first-line HER2 backbone replacement potential.

What changed

Ziihera’s overall survival beat over trastuzumab, raising first-line HER2 backbone replacement potential.

Why it matters

Ziihera’s overall survival beat over trastuzumab, raising first-line HER2 backbone replacement potential. — impact context not separately stored; see What changed.

Sources

eodhd